SCHEMBL2635901

SCHEMBL2635901

O=C(O)Cc1ccc(NC(=O)COc2cc(C(=O)O)cc3cc(Cl)cc(Cl)c23)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
POLB P06746 4/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
ACHE P22303 1/20 0.45
NR1H4 Q96RI1 3/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
DAPK1 P53355 1/20 0.41
PIM3 Q86V86 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635691 0.91 MAPT (0.47) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635923 0.91 MEN1 (0.52) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635233 0.90 MEN1 (0.49) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635701 0.89 MEN1 (0.60) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635404 0.89 MEN1 (0.54) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2636145 0.88 MEN1 (0.56) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL12004148 0.87 MEN1 (0.48) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635595 0.87 MEN1 (0.53) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635580 0.86 MEN1 (0.50) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL2635689 0.85 KMT2A (0.50) MEN1KMT2APOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US claimed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP claimed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO claimed
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 MEN1 932/4885KMT2A 2708/4885POLB 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.